- cafead Jan 18, 2020 at 07:52: PM
via Bayer and Merck & Co need Vitality data to breathe life into vericiguat, while Akero awaits its first big test with the Nash project AKR-001.
article source
article source
-
Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
- Thread starter cafead
- Start date
<
Similar threads